Measurement in Public Health: What pulmonary tuberculosis management has taught us;Evaluación en salud pública: Lecciones aprendidas de la gestión de la tuberculosis pulmonar

Gaceta Sanitaria

Volumn 22, Issue 4, 2008, Pages 362-370

  Chaulk, C Patrick ^a,b   Kazandjian, Vahé A ^b,c,e   Gutiérrez, Paula Vallejo ^d  

^a Annie E Casey Foundation   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c LogicQual Research Institute   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Center for Performance Sciences   (United States)

Author keywords

Continuum of care; DOT success rate; Pulmonary tuberculosis; Quality of care

Indexed keywords

EID: 48349087142     PISSN: 02139111     EISSN: 15781283     Source Type: Journal    
DOI: 10.1157/13125360     Document Type: Article

References (35)

1. Health care systems in eight countries: trends and challenges. En: Dixon A, Mossialos E, editors. London: London School of Economics & Political Science; 2002.
2. World Health Report 2005: annex table 6. Geneva: World Health Organization; 2005.
3. Grossman J, Mackenzie FJ. The randomized controlled trial: gold standard, or merely standard? Perspect Biol Med. 2005;48:516-34.
4. Simon SD. Is the randomized clinical trial the gold standard of research? J Androl. 2001;22:938-43.
5. Kaptchuk TJ. The double-blind, randomized, placebo-controlled trial: gold standard or golden calf? J Clin Epidemiol. 2001;54:541-9.
6. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy. 1999;4:112-21.
7. Herman J. Shortcomings of the randomized controlled trial: a view from the boondocks. J Eval Clin Pract. 1998;4:283-6.
8. Global Tuberculosis Control, WHO Report 2000. Geneva: Communicable Disease, World Health Organization; 2000.
9. Essential components of a tuberculosis prevention and control program. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep. 1995;44:1-16.
10. Davis MS. Variations in patients' compliance with doctors' orders: analysis of congruence between survey responses and results of empirical investigations. J Med Educ. 1966;41:1037-48.
11. Sbarbaro JA. Compliance: inducements and enforcements. Chest. 1979;76 Suppl 6:750-6.
12. Marston MV. Compliance with medical regimens: a review of the literature. Nurs Res. 1970;19:312-23.
13. Morrow R, Rabin DL. Reliability in self-medication with isoniazid, I & II [abstract]. Clin Res. 1066;13:362.
14. Charney E, Bynum R, Eldredge D, Frank D, MacWhinney JB, McNabb N, et al. How well do patients take oral penicillin? A collaborative study in private practice. Pediatrics. 1967;40:188-95.
15. Tuberculosis Program Management in the United States 1986-1991. Altanta: Centers for Disease Control and Prevention; 1993.
16. Bloch AB, Cauthen GM, Simone PM, Kelly GD, Dansbury KG, Castro KG. Completion of tuberculosis therapy for patients reported in the United States in 1993. Int J Tuberc Lung Dis. 1999;3:273-80.
17. Improving patient adherence to tuberculosis treatment. Atlanta: Centers for Disease Control and Prevention, US Department of Health and Human Services, Public Health Services; 1994.
18. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep. 1993;42:1-8.
19. Methods of WHO Report 2006. Global tuberculosis control: surveillance, planning, financing. Genova: World Health Organization; 2006.
20. Wilkinson D. High-compliance tuberculosis treatment programme in a rural community. Lancet. 1994;343:647-8.
21. Groups at risk: WHO report on the tuberculosis epidemic 1996. Geneva: World Health Organization; 1996.
22. Stake RE. Case studies. En: Denzin NK, Lincoln YS, editors. Clinical research. Handbook of qualitative research: London: Sage Publications; 1994. p. 236-48.
23. Alcaide Megias J, Pascual Torramade J, Altet Gómez MN, Maldonado Díaz de Losada J, López Espinosa F, Salleras Sanmartí L. Results and epidemiological impact of directly observed treatment of tuberculosis. Arch Bronconeumol. 1999;35:267-74.
24. Cayla JA, Caminero JA, Rey R, Lara N, Vallés X, Galdos-Tanguis H. Current status of treatment completion and fatality among tuberculosis patients in Spain. Int J Tuberc Lung Dis. 2004;8:458-64.
25. Manalo F, Tan F, Sbarbaro JA, Iseman MD. Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis. 1990;142:1301-5.
26. El-Sadr W, Medard F, Berthaud V, Barthaud V. Directly observed therapy for tuberculosis: the Harlem Hospital experience, 1993. Am J Public Health. 1996;86:1146-9.
27. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274:945-51.
28. Miller WL, Crabtree BF. Clinical research. En: Denzin NK, Lincoln YS, editors. Handbook of qualitative research. London: Sage Publications; 1994. p. 340-52.
29. Practice guidelines for public health. Assessment of scientific evidence, feasibility and benefits: a report of the guidelines development project for public health practice. Albany: Council on Linkages Between Academia and Public Health Practice; 1995.
30. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA. 1998;279:943-8.
31. Chaulk CP, Friedman M, Dunning R. Modeling the epidemiology and economics of directly observed therapy in Baltimore. Int J Tuberc Lung Dis. 2000;4:201-7.
32. Moore RD, Chaulk CP, Griffiths R, Cavalcante S, Chaisson RE. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med. 1996;154:1013-9.
33. Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest. 1997;112:63-70.
34. Innovative care for chronic conditions: building blocks for action: global report. WHO Library Cataloging-in-Publication Data, 2002 [citado 1 May 2007]. Disponible en: www.who.int/entity/diabetesactiononline/about/iccc_ch4.pdf
35. Kazandjian VA. Accountability through measurement: a global healthcare imperative. Milwaukee: ASQ Quality Press; 2002.